Home Cart Sign in  
Chemical Structure| 191217-81-9 Chemical Structure| 191217-81-9

Structure of Pramipexole 2HCl hydrate
CAS No.: 191217-81-9

Chemical Structure| 191217-81-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pramipexole 2HClis a non-ergoline dopamine (DA) agonist, used to treat Parkinson's disease.

Synonyms: Pramipexole 2HCl Monohydrate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pramipexole 2HCl hydrate

CAS No. :191217-81-9
Formula : C10H21Cl2N3OS
M.W : 302.26
SMILES Code : NC(S1)=NC2=C1C[C@@H](NCCC)CC2.[H]Cl.[H]Cl.[H]O[H]
Synonyms :
Pramipexole 2HCl Monohydrate
MDL No. :MFCD02183927
InChI Key :APVQOOKHDZVJEX-QTPLPEIMSA-N
Pubchem ID :166589

Safety of Pramipexole 2HCl hydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H336
Precautionary Statements:P301+P312+P330

Related Pathways of Pramipexole 2HCl hydrate

GPCR

Isoform Comparison

Biological Activity

Description
Pramipexole dihydrochloride hydrate, a hydrate form of Pramipexole, also crosses the BBB and retains the same selectivity for dopamine D2-type receptors. This form is used similarly for PD and RLS research[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary mouse astrocytes 100–400 μM 12 hours To investigate the effect of pramipexole on autophagy activity in astrocytes, results showed that pramipexole dose-dependently enhanced autophagy activity, evidenced by increased LC3-II and BECN1 protein expression and GFP-LC3 puncta formation. PMC9813225
IL-10-producing regulatory T cells 2 or 200 ng/mL 24 hours To investigate the role of IL-10 in the neuroprotective effect of pramipexole-treated Treg cells. Results demonstrated that IL-10-producing Treg cells significantly increased the survival rate of dopaminergic neurons and promoted axonal growth. PMC11298200

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Parkinson's disease model induced by bilateral striatal LPS injection Intraperitoneal injection 0.5 mg/kg Once daily for 3 or 21 days To investigate the effect of pramipexole on dopamine neuron damage and neuroinflammation in LPS-induced Parkinson's disease model, results showed that pramipexole significantly alleviated the loss of DA neurons and suppressed astrocyte activation and proinflammatory cytokine IL-1β levels. PMC9813225
C57BL/6 mice MPTP-induced Parkinson’s disease model Oral 3 mg/kg Once daily for 18 days To evaluate the protective effects of pramipexole on the MPTP-induced Parkinson’s disease model. Results showed that pramipexole protected mice against MPTP injuries, improved the loss of dopaminergic neurons, reduced the increase in α-synuclein, and protected the integrity of the blood-brain barrier. PMC5630672
Sprague-Dawley rats Highly impulsive (HI), moderately impulsive (MI), and low impulsive (LI) rat models Intraperitoneal injection 0.2 mg/kg Once daily for 12 sessions PPX significantly reduced impulsivity in highly impulsive rats and restored impulse control by modulating limbic frontostriatal circuits. PMC10858232
Sprague-Dawley rats AAV2-mediated A53T alpha-synuclein expression-induced nigrostriatal degeneration model Subcutaneous injection 0.3 mg/kg Once daily for 10 days To evaluate the effects of pramipexole on nigrostriatal degeneration. Results showed PPX restored burst firing patterns of OFC neurons but failed to counteract the negative effects of dopaminergic neurodegeneration on OFC-DMS pathway plasticity. PMC11385550
Mice Parkinson’s disease model mice Subcutaneous injection 0.3 mg/kg 10 consecutive days To evaluate the effect of pramipexole on decision-making behavior, results showed that pramipexole increased disadvantageous choices characterized by a high-risk/high-reward behavior. PMC11354263
Wistar rats Harmaline-induced tremor model Subcutaneous injection 0.1 mg/kg Single administration, measured for 60 minutes To examine the effects of pramipexole on harmaline-induced tremor, results showed that a low dose (0.1 mg/kg) of pramipexole significantly reversed the harmaline-induced increase in tremor. PMC6492867
Long-Evans rats Chronic inflammatory pain model (CFA-induced) Subcutaneous injection 1 mg/kg Acute treatment: single dose 1 h prior to testing; Repeated treatment: daily injections for 4 consecutive days To evaluate the effects of pramipexole on mechanical hypersensitivity in rats with chronic inflammatory pain. Results showed that both acute and repeated pramipexole treatment significantly attenuated mechanical hypersensitivity in CFA-treated animals but exhibited no analgesic effects in control animals. PMC10171400
Sprague-Dawley rats Subarachnoid hemorrhage model Intraperitoneal injection 0.25 mg/kg Once every 8 hours for 48 hours Pramipexole-induced hypothermia alleviates early brain injury after subarachnoid hemorrhage via PI3K/AKT/GSK3β signaling pathway PMC4812308
Long-Evans rats Probability-discounting task Subcutaneous injection 0.3 mg/kg Once daily for 7 days To test the effects of pramipexole on probability discounting and locomotor behavior. Results showed that pramipexole increased the choice of highly disadvantageous options and reduced phasic dopamine release in the nucleus accumbens. PMC5241163
Rats Harmaline-induced tremor model Subcutaneous injection 0.1 mg/kg Single dose, 30 minutes before harmaline Pramipexole reversed harmaline-induced tremor and increased zif-268 mRNA expression in the inferior olive, cerebellar cortex, and motor cortex, with tremor intensity positively correlating with zif-268 mRNA expression in these structures. PMC7297825
Long-Evans rats Parkinson's disease model Subcutaneous injection 0.3 mg/kg Once daily for 4 days To study the impact of pramipexole on probability discounting behavior, finding that pramipexole increased the propensity to engage in disadvantageous choices and was paralleled by a marked D3 receptor upregulation in the nucleus accumbens. PMC9012661
Sprague-Dawley rats Conditioned reinforcement model Subcutaneous injection 0.1 mg/kg, 0.32 mg/kg, or 1.0 mg/kg Administered during ACQ2-8 and ACQ10-14, with sessions starting 10 min after injection Pramipexole dose-dependently increased active responding without changing inactive responding, and this enhancement was blocked by L-741,626 but not SB-277011A PMC4282623

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01525641 - Completed - -
NCT01525641 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.54mL

3.31mL

1.65mL

33.08mL

6.62mL

3.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories